JP2022545917A5 - - Google Patents

Info

Publication number
JP2022545917A5
JP2022545917A5 JP2022513154A JP2022513154A JP2022545917A5 JP 2022545917 A5 JP2022545917 A5 JP 2022545917A5 JP 2022513154 A JP2022513154 A JP 2022513154A JP 2022513154 A JP2022513154 A JP 2022513154A JP 2022545917 A5 JP2022545917 A5 JP 2022545917A5
Authority
JP
Japan
Prior art keywords
cancer
tff2
modified
polypeptide
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022513154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022545917A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/000699 external-priority patent/WO2021038296A2/en
Publication of JP2022545917A publication Critical patent/JP2022545917A/ja
Publication of JP2022545917A5 publication Critical patent/JP2022545917A5/ja
Priority to JP2025086620A priority Critical patent/JP2025158975A/ja
Pending legal-status Critical Current

Links

JP2022513154A 2019-08-27 2020-08-27 修飾tff2ポリペプチド Pending JP2022545917A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025086620A JP2025158975A (ja) 2019-08-27 2025-05-23 修飾tff2ポリペプチド

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962892520P 2019-08-27 2019-08-27
US62/892,520 2019-08-27
US201962943803P 2019-12-04 2019-12-04
US62/943,803 2019-12-04
US202063041097P 2020-06-18 2020-06-18
US63/041,097 2020-06-18
PCT/IB2020/000699 WO2021038296A2 (en) 2019-08-27 2020-08-27 Modified tff2 polypeptides

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025086620A Division JP2025158975A (ja) 2019-08-27 2025-05-23 修飾tff2ポリペプチド

Publications (2)

Publication Number Publication Date
JP2022545917A JP2022545917A (ja) 2022-11-01
JP2022545917A5 true JP2022545917A5 (https=) 2023-09-05

Family

ID=72659816

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022513154A Pending JP2022545917A (ja) 2019-08-27 2020-08-27 修飾tff2ポリペプチド
JP2025086620A Pending JP2025158975A (ja) 2019-08-27 2025-05-23 修飾tff2ポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025086620A Pending JP2025158975A (ja) 2019-08-27 2025-05-23 修飾tff2ポリペプチド

Country Status (9)

Country Link
US (1) US20220281939A1 (https=)
EP (1) EP4021479A2 (https=)
JP (2) JP2022545917A (https=)
CN (1) CN115551530A (https=)
AU (1) AU2020338947A1 (https=)
CA (1) CA3152665A1 (https=)
IL (1) IL290910A (https=)
MX (1) MX2022002337A (https=)
WO (1) WO2021038296A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111265528A (zh) 2020-01-21 2020-06-12 中国人民解放军军事科学院军事医学研究院 法匹拉韦在治疗冠状病毒感染方面的应用
WO2021183259A1 (en) * 2020-03-12 2021-09-16 Nanopharmaceutics, Inc. Famotidine and famotidine analogs for corona virus treatment
JP7579880B2 (ja) * 2020-03-30 2024-11-08 山東睿鷹制薬集團有限公司 新型コロナウイルス感染の治療におけるTFF2タンパク質とIFN-κタンパク質の併用の応用
AU2022274703A1 (en) * 2021-05-12 2023-08-17 Alkahest, Inc. Methods and compositions for treating aging-associated impairments with trefoil factor family member 2 modulators
EP4089133A1 (en) * 2021-05-14 2022-11-16 Johannes Gutenberg-Universität Mainz Poly(ethylene glycol) having c1 to c3-alkyloxymethyl side chains, bioconjugates thereof, process for its preparation and its use.
CN113940310A (zh) * 2021-10-26 2022-01-18 浙江大学 一种小鼠胃癌模型的建立方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
CA1202840A (en) 1985-06-10 1986-04-08 Jonathan R. Kleinsasser Combination wet and dry feeder for animals
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4710384A (en) 1986-07-28 1987-12-01 Avner Rotman Sustained release tablets made from microcapsules
US5186933A (en) 1986-12-30 1993-02-16 Baylor College Of Medicine Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5194376A (en) 1989-02-28 1993-03-16 University Of Ottawa Baculovirus expression system capable of producing foreign gene proteins at high levels
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5766897A (en) 1990-06-21 1998-06-16 Incyte Pharmaceuticals, Inc. Cysteine-pegylated proteins
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5846951A (en) 1991-06-06 1998-12-08 The School Of Pharmacy, University Of London Pharmaceutical compositions
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US5919455A (en) 1993-10-27 1999-07-06 Enzon, Inc. Non-antigenic branched polymer conjugates
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5721121A (en) 1995-06-06 1998-02-24 Genentech, Inc. Mammalian cell culture process for producing a tumor necrosis factor receptor immunoglobulin chimeric protein
US20030186882A1 (en) * 2001-07-31 2003-10-02 Podolsky Daniel K. Methods and compositions for treating and preventing distal bowel lesions
US5985263A (en) 1997-12-19 1999-11-16 Enzon, Inc. Substantially pure histidine-linked protein polymer conjugates
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
CN101255192A (zh) 2000-05-26 2008-09-03 布里斯托尔-迈尔斯斯奎布公司 可溶性ctla4突变体分子及其应用
EP2295450B1 (en) 2000-09-29 2015-01-28 Merck Sharp & Dohme Corp. Pegylated interleukin-10
US8129330B2 (en) 2002-09-30 2012-03-06 Mountain View Pharmaceuticals, Inc. Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof
US7610156B2 (en) 2003-03-31 2009-10-27 Xencor, Inc. Methods for rational pegylation of proteins
CN1863551A (zh) * 2003-07-31 2006-11-15 抗癌公司 用于提高在体内的效力的PLP和PEG-rMETase的用途
US7524813B2 (en) * 2003-10-10 2009-04-28 Novo Nordisk Health Care Ag Selectively conjugated peptides and methods of making the same
CA2581423A1 (en) * 2004-09-23 2006-03-30 Vasgene Therapeutics, Inc. Polipeptide compounds for inhibiting angiogenesis and tumor growth
EP1836316A4 (en) 2004-12-22 2009-07-22 Ambrx Inc PROCESS FOR EXPRESSION AND CLEANING OF RECOMBINANT HUMAN GROWTH HORMONE
JP2008525479A (ja) * 2004-12-22 2008-07-17 オークランド ユニサービシス リミテッド トレフォイル因子およびそれを用いた増殖性疾患の処置方法
SI2173890T1 (sl) 2007-06-21 2011-06-30 Univ Muenchen Tech Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost
ES2610356T3 (es) 2009-02-03 2017-04-27 Amunix Operating Inc. Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos
WO2011008495A2 (en) 2009-06-29 2011-01-20 The Board Of Regents Of The University Of Texas System Arginase formulations and methods
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
EP2536753B1 (en) 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
US9221882B2 (en) 2010-05-21 2015-12-29 Technische Universitat Munchen Biosynthetic proline/alanine random coil polypeptides and their uses
CN103096917A (zh) * 2010-06-04 2013-05-08 三叶草私人有限公司 用于治疗慢性肺病的三叶因子(tff)
JP2014520094A (ja) 2011-05-27 2014-08-21 バクスター・インターナショナル・インコーポレイテッド 増加した半減期を有する治療用タンパク質およびそれを調製する方法
WO2013176785A1 (en) * 2012-05-21 2013-11-28 The Trustees Of Columbia University In The City Of New York Trefoil family factor and uses thereof
EP3842448A1 (en) 2015-05-15 2021-06-30 City of Hope Chimeric antigen receptor compositions
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
RU2021135949A (ru) * 2016-09-13 2022-04-14 Интрексон Актобиотикс Н.В. Мукоадгезивный микроорганизм
WO2018132768A1 (en) 2017-01-13 2018-07-19 Sanna Pietro P Methods and compositions for treating hpa hyperactivity
US10174302B1 (en) 2017-06-21 2019-01-08 Xl-Protein Gmbh Modified L-asparaginase

Similar Documents

Publication Publication Date Title
JP2022545917A5 (https=)
US20230220034A1 (en) Method for improving solubility of protein and peptide by using immunoglogulin fc fragment linkage
Gebauer et al. Prospects of PASylation® for the design of protein and peptide therapeutics with extended half-life and enhanced action
TWI731015B (zh) 三重升糖素/glp-1/gip受體促效劑之長效接合物
AU690555B2 (en) Vitamin B-12 mediated oral delivery systems for GCSF and EPO
JP5653214B2 (ja) 細胞膜透過性ペプチド
EP2585098B1 (en) Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules for use in treating obesity and obesity-related disorders
CN104302772A (zh) 用于糖尿病治疗的蛋白、蛋白缀合物及其应用
JP7761557B2 (ja) グルカゴン、及びglp-1受容体及びgip受容体二重アゴニストを含む組成物及びその治療学的使用
CN1126441A (zh) 使用聚合物放大维生素b12吸收系统
CN104684576A (zh) 聚乙二醇化的oxm变体
JPH09506087A (ja) 改良されたインターフェロン−ポリマー複合体
IL285716B (en) Compacted molecules derived from colic toxin for oral delivery of biologically active cargo
CN113453703A (zh) 包括胰岛素和对胰高血糖素和glp-1和gip受体均具有活性的三重激动剂的药物组合物
JP2018517697A (ja) ペグ化オキシントモジュリン変異体
CN117018216A (zh) 与白蛋白具有较佳结合亲和力的药物分子
TW202415676A (zh) 升糖素樣肽-1受體拮抗劑
JP2022535685A (ja) ビオチン部分に結合した生理活性物質、及びその生理活性物質を含む経口投与用組成物
US20250121086A1 (en) Liver-targeted substance and use thereof
HK40052306A (en) Composition for improving the solubility of a protein or peptide by using immunoglobulin fc fragment linkage
CN120475984A (zh) Dna-trail复合物及其治疗肿瘤的用途
BR112016022844B1 (pt) Método e composição para aperfeiçoar a solubilidade de proteína e peptídeo em solução aquosa que compreende um fragmento fc de imunoglobulina
EA040489B1 (ru) Способ улучшения растворимости белка и пептида за счет использования связывания с фрагментом fc иммуноглобулина
JP2019514859A (ja) 病的な筋肉減少および筋力低下の処置のためのnope
HK1182312B (en) Fzd8 extracellular domains and fzd8 extracellular domain fusion molecules for use in treating obesity and obesity-related disorders